As many patients only weakly respond to anti-TNF-α therapy, or even become resistant to it [19], blocking of TNF-β in combination with other TNF family members may be useful in the development of future new therapies for the treatment of inflammatory joint diseases such as RA. This evidence concerns the gene TNF and rheumatoid arthritis.